Clinical trial
Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
NCT04291703 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 1, 2023
- Completion date
- December 17, 2024
- Enrollment
- 2 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.